The Vein & Aesthetic Center of Boston is pleased to offer Kybella, the first FDA-approved non-surgical treatment that effectively shrinks submental fat, also known as “double chin.” This treatment is especially exciting because prior to Kybella, the only option for targeting this hard-to-treat area was liposuction, a surgical procedure.

The “double chin” effect can be due to a variety of causes in both men and women. Genetics, weight gain, and aging can all contribute to the fat collection in the under chin area, which, even with diet and exercise, may not disappear. Excess fat in this area can make you look older and heavier than you actually are.

When Kybella is injected into the fat beneath your chin, it destroys fat cells, which can then no longer store or accumulate fat. Fat cleared from the treatment area is processed through your body’s natural metabolism.

In clinical studies, 79% of people treated with Kybella had improved satisfaction with the appearance of the area beneath their chin (compared with 34% of people treated with placebo) 12 weeks after last treatment (source: Kybella patient brochure).

Kybella on Good Morning America

Kybella on The Today Show

Frequently Asked Questions:

What is Kybella and how does it work?
Kybella is the first and only FDA-approved injectable treatment to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells. The active ingredient in Kybella is deoxycholic acid, a naturally occurring molecule in the body, that aids in the breakdown and absorption of dietary fat. When Kybella is injected into the subcutaneous fat in the chin area, it causes the destruction of fat cells, which are then unable to store or accumulate fat.

What can I expect during a Kybella treatment?
During your appointment, our doctors will create a tailored treatment plan based on your chin profile and your desired results. The submental area (under the chin) will be cleaned and prepped. Typically, an ice pack will be used to numb the area and make the injections very tolerable. Kybella will then be injected into 10 to 20 sites. The amount injected and number of treatments recommended will be determined by the amount of fullness in the individual and their desired results. 2 to 6 treatments are typically required to achieve maximum results.

How long does treatment with Kybella last?
When injected into fat under the chin, KYBELLA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After reaching your desired aesthetic, further treatment is not expected.

What are the possible side effects of treatment with Kybella?
The most common side effects of Kybella are swelling, bruising, pain, numbness, redness and areas of hardness around the treatment area. Serious side effects include trouble swallowing and nerve injury in the jaw that can temporarily cause an uneven smile or facial muscle weakness. In clinical studies, nerve injury in the jaw resolved on its own in a median of 44 days (range of 1 to 298 days), and trouble swallowing resolved on its own in a median of 3 days (range of 1 to 81 days).

Contact The Vein & Aesthetic Center of Boston today to schedule your Kybella consultation and find out if this exciting new treatment is right for you!


Indication and Important Safety Information
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
Adverse Reactions
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Download KYBELLA® full prescribing information